Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury.

Pubmed ID: 18074478

Pubmed Central ID: PMC3293249

Journal: Critical care medicine

Publication Date: Dec. 1, 2007

Affiliation: Division of Nephrology, University of California, San Francisco, CA, USA. Kathleen.liu@ucsf.edu

MeSH Terms: Humans, Male, Female, Receptors, Tumor Necrosis Factor, Logistic Models, Middle Aged, Survival Analysis, ROC Curve, Risk Assessment, Multivariate Analysis, Kidney Function Tests, Predictive Value of Tests, Intensive Care Units, Acute Kidney Injury, Immunoglobulin G, Plasminogen Activator Inhibitor 1, Interleukin-6, Biomarkers, Etanercept, Respiratory Distress Syndrome

Grants: R37 HL051856, R37 HL051856-14, 8 K12 RR023262, N01-HR46054-46064, N01HR46054, K12 RR023262

Authors: Thompson BT, Parsons PE, Matthay MA, Ware LB, Eisner MD, Korpak A, Liu KD, Glidden DV, Wheeler A, Chertow GM

Cite As: Liu KD, Glidden DV, Eisner MD, Parsons PE, Ware LB, Wheeler A, Korpak A, Thompson BT, Chertow GM, Matthay MA, National Heart Lung and Blood Institute ARDS Network Clinical Trials Group. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med 2007 Dec;35(12):2755-61.

Studies:

Acute Respiratory Distress Network (ARDSNet) Studies 01 and 03 Lower versus higher tidal volume, ketoconazole treatment and lisofylline treatment (ARMA/KARMA/LARMA)

Abstract

OBJECTIVE: To identify biological and clinical predictors of acute kidney injury in subjects with acute lung injury. DESIGN: Secondary data analysis from a multicenter, randomized clinical trial. SETTING: Intensive care units in ten university medical centers. PATIENTS: A total of 876 patients enrolled in the first National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Network trial. INTERVENTIONS: Study subjects were randomized to receive a low tidal volume ventilation strategy and pharmacologic therapy with ketoconazole or lisofylline in a factorial design. MEASUREMENTS AND MAIN RESULTS: We tested the association of baseline levels of interleukin-6, interleukin-8, interleukin-10, von Willebrand factor, tumor necrosis factor-[alpha], type I and II soluble tumor necrosis factor receptors (sTNFR-I and -II), protein C, plasminogen activator inhibitor-1 (PAI-1), surfactant protein-A, surfactant protein-D, and intracellular adhesion molecule-1 with subsequent acute kidney injury. Of 876 study participants who did not have end-stage renal disease, 209 (24%) developed acute kidney injury, defined as a rise in serum creatinine of >50% from baseline over the first four study days. The 180-day mortality rate for subjects with acute kidney injury was 58%, compared with 28% in those without acute kidney injury (p < .001). Interleukin-6, sTNFR-I, sTNFR-II, and PAI-1 levels were independently associated with acute kidney injury after adjustment for demographics, interventions, and severity of illness. A combination of clinical and biological predictors had the best area under the receiver operating characteristic curve, and the contribution of sTNFR-I and PAI-1 to this model was highly significant (p = .0003). CONCLUSIONS: Elevations in PAI-1, interleukin-6, and the sTNFRs in subjects with acute kidney injury suggest that disordered coagulation, inflammation, and neutrophil-endothelial interactions play important roles in the pathogenesis of acute kidney injury. The combination of these biological and clinical risk factors may have important and additive value in predictive models for acute kidney injury.